BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Morokutti-Kurz, M., Fröba, M., Graf, P., Große, M., Grassauer, A., & Auth, J., et al. (2021). Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro. PloS one, 16(2), e0237480. Added by: Dr. Enrique Feoli (07/02/2022, 17:26) Last edited by: Dr. Enrique Feoli (07/02/2022, 17:27) |
 |
| Resource type: Journal Article DOI: 10.1371/journal.pone.0237480 ID no. (ISBN etc.): 1932-6203 BibTeX citation key: MorokuttiKurz2021 View all bibliographic details  |
Categories: BioAcyl Corp Subcategories: Polysulfate polianions Creators: Auth, Fröba, Graf, Grassauer, Große, Morokutti-Kurz, Prieschl-Grassauer, Schubert Collection: PloS one |
Views: 2/266
|
| Abstract |
|
In the absence of a vaccine and other effective prophylactic or therapeutic countermeasures the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) remains a significant public health threat. Attachment and entry of coronaviruses including SARS-CoV-2 is mainly mediated by the spike glycoprotein. Here, we show that iota-carrageenan can inhibit the cell entry of the SARS-CoV-2 spike pseudotyped lentivirus in a dose dependent manner. SARS-CoV-2 spike pseudotyped lentivirus particles were efficiently neutralized with an IC50 value of 2.6 μg/ml iota-carrageenan. Experiments with patient isolated wild type SARS-CoV-2 virus showed an inhibition of replication in a similar range. In vitro data on iota-carrageenan against various Rhino- and endemic Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction of severity and duration of symptoms of common cold caused by various respiratory viruses. Accordingly, our in vitro data on SARS-CoV-2 spike pseudotyped lentivirus and replication competent SARS-CoV-2 suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections.
|
| Notes |
|
Publisher: Public Library of Science
|